Described herein are methods and compositions forinter alialowering the specific gravity of urine and lowering the calcium oxalate risk index of in felines. In particular, diets and methods utilizing certain amounts and ratios of arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions

The present invention relates to furazidin for vaginal use in the treatment of a bacterial vaginal infection. Preferably, the bacterial vaginal infection is caused by Gardnerella vaginalis and/or Atopobium vaginae bacteria.

The present invention discloses a glycosylated oxalate decarboxylase. The oxalate decarboxylase is derived from edible basidiomycetes, the glycosylated oxalate decarboxylase has an enzyme activity at the pH value of 1.5-7.5, the activity at the pH value of 1.5-2.0 is 10% greater than the optimum activity, and a specific activity is more than 2 U/mg. The present invention also discloses preparation and application of the glycosylated oxalate decarboxylase. The glycosylated oxalate decarboxylase disclosed by the present invention can keep the activity under a low pH value, and can effectively prevent and treat kidney stones.

A compound represented by the formula (1), or a salt thereof (X represents carbonyl group, or sulfonyl group; R.sup.1 represents hydrogen atom, a halogen atom, an alkyl group, an alkanoyl group, cyano group, or carboxyl group; R.sup.2 represents an alkyl group, a cyclic carbon group, or a heterocyclic group; R.sup.3 represents hydrogen atom, or 1 to 3 substituents; R.sup.4 and R.sup.5 represents hydrogen atom, a halogen atom, or an alkyl group; and R.sup.6 represents an alkyl group, or an alkoxy group), which has an mPGES-1 inhibitory action, and is useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of inflammation, pain, rheumatism, and the like.

##STR00001##

2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid is useful in the modulation of blood or serum uric acid levels. In some embodiments, 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid is used in the treatment or prevention of disorders related to aberrant levels of uric acid. In some embodiments, 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid is used for reducing serum uric acid levels in a human. Also described herein are compositions comprising 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, and their use in the modulation of blood or serum uric acid levels.

Embodiments described herein generally relate to compositions and methods requiring these compositions that may act to reduce the incidence and/or reoccurrence of kidney stones and/or other pathological calcification diseases, symptoms, or conditions. The compositions include a polyphosphate material, which may be method of treating pathological calcification. In some embodiments, the polyphosphate material included in the composition to be administered may be a linear tripolyphosphate material or a hexametaphosp hate material.

Embodiments described herein generally relate to compositions and methods requiring these compositions that may act to reduce the incidence and/or reoccurrence of kidney stones and/or other pathological calcification diseases, symptoms, or conditions. The compositions include a polyphosphate material, which may be method of treating pathological calcification. In some embodiments, the polyphosphate material included in the composition to be administered may be a linear tripolyphosphate material or a hexametaphosp hate material.

The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions and microspheres that exhibit high affinity for mineralized metals. The present disclosure also provides strategies for using said compounds, compositions and microspheres in the treatment of nephrolithiasis or kidney stone disease, and methods of manufacturing and preparing said compounds and compositions.

The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions and microspheres that exhibit high affinity for mineralized metals. The present disclosure also provides strategies for using said compounds, compositions and microspheres in the treatment of nephrolithiasis or kidney stone disease, and methods of manufacturing and preparing said compounds and compositions.